Phenylalanine Ammonia-Lyase Activity Assay Kit
The Californer/10093577

MILPITAS, Calif. - Californer -- Phenylalanine Ammonia-Lyase (PAL, EC 4.3.1.24) catalyzes the reversible non-oxidative deamination of L-phenylalanine to transcinnamic acid and ammonia without any external cofactors. PAL is expressed in plants, yeast and some fungi and is absent in bacteria and animals. Patients suffering from the genetic disorder, phenylketonuria is unable to metabolize phenylalanine that leads to irreversible cognitive impairment. Historically, phenylketonuria has been treated with a phenylalanine-restricted diet taken for the entirety of the patient's life. Recently, a drug containing PEGylated PAL has been FDA-approved to treat phenylketonuria, limiting the need of a restricted diet. BioVision's Phenylalanine Ammonia-Lyase Activity Assay Kit measures the activity of PAL via a two-step plate-based assay. The products of the PAL enzymatic reaction, generated in the first step, react with the developers resulting in the formation of a fluorescent compound, which is detected at Ex/Em = 410/470 nm. The kit can detect as low as 3 µU (3 pmol substrate catalysis/minute) of PAL under assay conditions.

More on The Californer

• New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
• Author Explodes Damning Myths about Hunger in America
• California: Happy Birthday, National Guard!
• Umbrella by J French Premieres Live at 8586 in the Beverly Center on December 22
• Affordable Luxury Bracelets to Gift This Christmas: Timeless Style with 40% Holiday Savings

Figures. (a). Ammonium Chloride Standard Curve. (b). Pooled normal human male AB serum was spiked with 5.5, 9.3, 12.7 and 20.6 µU of PAL respectively. The corresponding units of PAL recovered were 4.3, 8.8, 13.2 and 19.7 µU (recovery rates ranging from 78.4- 103.7%). The data shown is the average of three replicates where experiments were performed according to the kit protocol.

For more information on this assay kit, visit:https://bit.ly/3clJWDw

www.BioVision.com